<DOC>
	<DOCNO>NCT00671853</DOCNO>
	<brief_summary>The primary objective test hypothesis Quetiapine XR ( Extended Release ) monotherapy adjunctive therapy effective acute treatment bipolar depression comorbid generalize anxiety disorder patient bipolar disorder without substance use disorder . The secondary aim generate estimate effect size power definitive large-scale , multi-site collaborative R01 configure use primary secondary outcome measure definitive large-scale study .</brief_summary>
	<brief_title>Quetiapine Extended Release ( XR ) Bipolar Patients With Comorbid Generalized Anxiety Disorder ( GAD )</brief_title>
	<detailed_description>120 subject age 18 Diagnostic Statistical Manual -IV Generalized Anxiety Disorder Bipolar Disorder type I II identify extensive clinical interview Mini-International Neuropsychiatric Interview ( MINI ) enrol randomize . Assignment arm balance BP I vs BP II ; male vs female ; v without SUD . Potential participant recruit mean Institutional Review Board -approved advertise clinical psychiatric infrastructure . This study randomize , double-blind , placebo-controlled , 8-week comparison quetiapine sustained-release monotherapy adjunctive mood stabilizer therapy vs. placebo acute treatment comorbid generalize anxiety disorder patient bipolar disorder without substance use disorder . Subjects assess weekly mood change side effect .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Diagnostic Statistical ManualIV diagnosis bipolar I II disorder , currently depress confirm MINIPlus Screening . Diagnostic Statistical ManualIV diagnosis lifetime GAD ; Hamilton Depression Rating Scale 17 item total score ≥ 18 ; Hamilton Anxiety Rating Scale total score ≥ 18 ; Be male female least 18 year old old 65 . Pregnancy breast feed . Severe medical neurological problem . Severe personality disorder . Currently suicidal risk judge physician . Known history intolerance hypersensitivity medication involve study . Treatment quetiapine dose 6 month prior randomization . Known lack response quetiapine dosage least 50 mg 4 week time , judge investigator . Dependence opiate , phencyclidine ( PCP ) , and/or barbiturate . Acute mania determine score &gt; 12 Young Mania Rating Scale baseline . Concurrent obsessive compulsive disorder . Use follow cytochrome P450 3A4 inhibitor 14 day precede enrolment include limited : ketoconazole , itraconazole , fluconazole , erythromycin , clarithromycin , troleandomycin , indinavir , nelfinavir , ritonavir , fluvoxamine saquinavir Use follow cytochrome P450 inducers 14 day precede enrollment include limited : phenytoin , carbamazepine , barbiturate , rifampin , St. John 's Wort , glucocorticoid Administration depot antipsychotic injection within one dose interval ( depot ) randomisation Medical condition would affect absorption , distribution , metabolism , excretion study treatment Unstable inadequately treat medical illness ( e.g . diabetes , angina pectoris , hypertension ) judge investigator Involvement planning conduct study Previous enrolment randomisation treatment present study . Participation another drug trial within 4 week prior enrolment study long accordance local requirement A patient diabetes mellitus ( DM ) fulfil one follow criterion : a. Unstable DM define enrollment glycosylated hemoglobin ( HbA1c ) .8.5 % b . Admitted hospital treatment DM DM relate illness within past 12 week c. Not physician care DM d. Physician responsible patient 's DM care indicate patient 's DM control f. Physician responsible patient 's DM care approve patient 's participation study g. Has dose oral hypoglycemic drug ( ) and/or diet 4 week randomization . For thiazolidinediones ( glitazones ) period le 8 week randomization h. Taking insulin whose daily dose one occasion past 4 week 10 % mean dose precede 4 week Note : If patient DM meet one criterion , patient exclude even treat physician believe patient stable participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Anxiety</keyword>
	<keyword>Anxiety Disorders</keyword>
	<keyword>Substance Use Disorders</keyword>
</DOC>